Summary As in many areas of health care, treatments for cancer may differ only moderately in their effects on major end points, such as death. But, such differences are worth knowing about, particularly in common diseases in which they could represent a substantial benefit to public health. Large-scale randomized evidence allows moderate differences to be investigated reliably, and one way to achieve this is by metaanalyses of updated and centrally collected individual patient data from all relevant trials. This paper illustrates why this form of research can often be important in cancer. It also offers the first list of such projects, as a source of information on current and past research in this area.
The conduct of meta-analyses of updated and centrally collected individual patient data (IPD) from all relevant randomized controlled trials has been discussed previously (Stewart and Clarke, 1995) . This paper illustrates why this form of research is often particularly important in cancer. It also publishes the first list of IPD meta-analyses in cancer (see Appendix), thereby providing an important source of information on what research has been, or is being, conducted in this area. It may also help avoid duplication of effort as IPD meta-analyses generally involve considerable work, particularly for those who organize them.
THE NEED FOR SYSTEMATIC REVIEWS TO ASSESS TREATMENTS FOR CANCER
As in many areas of health care, a fundamental principle underlying the need for large-scale randomized evidence in cancer is that, for major end points, the difference between the treatments under investigation is unlikely to be large. But, if a widely practicable treatment produced a moderate improvement for a common disease, this could represent a substantial benefit to public health. Similarly, clear and reliable evidence that there is no such difference could avoid much unnecessary treatment, along with its associated toxicity and cost (Collins et al, 1996) .
Large-scale randomized evidence can be obtained by suitably large randomized controlled trials (RCTs) that will accrue future patients, systematic reviews of past trials or ideally a combination of the two. At present, most trials in cancer are of limited size and so this disease is particularly well suited to systematic review. In addition, some treatments have been investigated in numerous RCTs over many years. For example, more than 40 000 women world-wide have, since 1974, been randomized into at least 50 separate trials of tamoxifen vs no tamoxifen for operable breast cancer. Data from approximately 30 000 women in 40 of the trials rather than factors such as quality of life. Some work has been carried out to combine the results of an IPD meta-analysis of recurrence and survival with average toxicity information from other sources to obtain a clearer idea of the influence of different treatments on a patient's quality of life (Gelber et al, 1996) but, in general, quality of life has not been measured in many trials and, when it has been measured, it is likely to prove difficult to combine the different measures used.
THE ADVANTAGES OF SYSTEMATIC REVIEWS BASED ON INDIVIDUAL PATIENT DATA TO ASSESS TREATMENTS FOR CANCER
Among the advantages of using IPD in any systematic review are that analyses can include time-to-event calculations; consistently defined patient subgroup and outcome analyses can be performed; and standardized checking and correction procedures can be followed for the data from each trial. It might also be easier for reviewers to obtain additional or updated information on individual patients. These advantages should be true for all forms of health care that can be subjected to systematic review but their relative importance will, of course, vary. Examples of how they have applied in IPD meta-analyses of treatments for cancer are given below.
Time to event analyses
This major advantage of collecting IPD can be obtained even if an absolute minimum amount of data is collected, namely the allocated treatment and the time interval to the outcome under investigation. Typically, more data than these are sought on each randomized patient, but even this minimum would allow summary statistics based on the entire survival experience to be calculated and a survival curve to be constructed. In cancer trials and reviews, the primary outcome of interest is often death and so these analyses may reveal an important prolongation of survival, which might not be apparent if follow-up data for a fixed point in time were collected.
For example, the IPD that were collected for a meta-analysis of platinum-based combination chemotherapy vs single non-platinum drugs in the treatment of advanced ovarian cancer showed that a reliance on 2-year survival data would exaggerate the difference between the two treatments. As Table 1 shows, the improvements in survival for patients allocated to combination chemotherapy compared with those allocated to a single drug are clearly at their greatest at 2 years and subsequently there is little difference between the two treatments (Stewart and Parmar, 1993) . Aggregate data could, of course, be requested from each trial for each time point to perform these analyses, but this approach will give less sensitive results, especially when the event rate is high.
Consistency of effect in patient subgroups
In small trials and reviews, subgroup or multiple outcome analyses may lead to misleading conclusions but if large-scale randomized evidence is available then this can be used, with appropriate caution, in determining whether the differences between treatments are greater for particular groups of patients. However, any such analyses should, ideally, be regarded as hypothesis-generating, for testing in future studies. If subgroup analyses are to be performed, they need to be as complete as possible and should preferably involve commonly defined subgroups and outcomes across all of the trials in a review. This will rarely be possible if the review is based solely on the published literature as, regardless of the problems associated with not being able to include unpublished trials, the information that has been published on various subgroup analyses may well be incomplete and is probably biased. Although trialists could be asked to fill in a table containing aggregate data on different types of patient and of outcome, this might prove difficult for many trialists, particularly for those with no data management or statistical support. In addition, if the outcome data had also to be supplied for different lengths of follow-up, the necessary tables could potentially contain more cells than patients in a trial. To complete such a table, the trialists would also need to adopt the centrally determined definitions for subgroups and outcomes. Thus, the collection of IPD may prove simpler for the trialists. It also allows the secretariat to prepare the necessary files for analysis and to apply consistent subgroup and outcome definitions across the included trials.
For example, in acute leukaemia, it is usual to distinguish between children and adults both in trials and in clinical practice generally. However, the definition of a child varies between trialists. Some trials in the USA have included patients up to 21 years of age (van Eys et al, 1989) , whereas childhood trials in the UK are often restricted to those aged 14 years and younger (Chessells et al, 1995) . A consequent advantage of an IPD meta-analysis is that a common definition of such a patient characteristic can be used across all the trials. This has recently been performed to investigate the duration and intensity of therapy for childhood acute lymphoblastic leukaemia (Childhood ALL Collaborative Group, 1996) . It is also possible that the data collected for an IPD metaanalysis could be used to investigate the effects of treatment if varying definitions are used for a particular subgroup.
Leukaemia also provides a useful example of when there may be a variety of definitions for a particular outcome. This is so with 'event-free survival', in which the outcomes considered as 'events' may vary between trial groups. If the relevant data on each possible contributing event are collected from each trial then a common definition can be adopted (Childhood ALL Collaborative Group, 1996) . Again, the IPD meta-analysis might also allow for the presentation of results from each of the contributing events separately so that the reader of the review can obtain an estimate of the relative effects of treatment on whatever they define as 'event-free survival'.
Checking and correction of data Although our combined experience is that fraud in trials appears to be rare; errors, misunderstandings or inadvertently inappropriate analyses are not and the ability to check the individual patient data may reveal problems or misunderstandings that can be resolved through consultation with the trialists. This can be particularly important in the treatment of cancer as such trials tend to run over relatively long periods of time and are, therefore, particularly susceptible to design changes during their course. As an example, it might be decided that one of the treatments in a two-arm trial should be stopped and so allocations to that arm are closed even though accrual may continue to the other treatment group. Only the patients who were concurrently randomized in such a study should be analysed for comparative purposes, but this is not always done. If the individual patient data are available then this can be rectified (Birch et al, 1988; Pignon et al, 1992) . In addition, checking of the raw data might reveal that a trial had used a quasirandom method of allocation (e.g. alternation or odd/even birth date) and, because of the danger that such schemes can lead to bias, these trials might then be excluded from the meta-analysis.
Obtaining unpublished additional data
As already noted, death is often one of the most important measures of outcome in cancer trials. In malignancies with very poor prognosis, a large proportion of patients will die relatively quickly and follow-up of a few years may be sufficient to obtain a reliable estimate of the relative efficacy of the treatments under investigation. However, in some diseases (such as early-stage breast or prostate cancer), many patients who will eventually die of their disease might live several years beyond diagnosis and primary treatment. It could then be many years or decades before a reliable estimate of the mortality effects of the different treatments can be made. This may be true for overall mortality, but it might be especially true for cause-specific mortality (or for the incidence of second cancers) if the treatments have long-term hazards. IPD meta-analyses are a means by which this can be investigated and may be the best way for some long-term effects to be assessed. By periodically collecting updated data on each patient, the amount of follow-up can be continually extended and if the end point of interest is death this can sometimes be achieved through the use of national mortality records, either by the trialists or by the reviewer (Stewart and Clarke, 1995) . Similarly, cancer registries might be used to help collect data on the diagnosis of second cancers. If a central database has already been prepared that contains the necessary baseline variables for each patient, it is a relatively easy task to add this type of additional follow-up information, if it is available, before conducting new analyses.
As an example of the importance of continuing to extend the follow-up in a disease such as breast cancer, the collaborators in the EBCTCG overview were, in 1990, sent a questionnaire asking them to predict the 10-year survival rates, after having seen the 5-year results in 1985 (EBCTCG, 1988) . Of the 78 trialists who responded, none predicted that the treatments given during the first few years after diagnosis would produce additional benefits between years 5 and 10 as great as those actually observed (Clarke and Stewart, 1994) .
As well as providing unexpected findings on overall mortality during longer follow-up, an IPD meta-analysis might also allow the investigation of cause-specific mortality (e.g. long-term fatal side-effects). This can be particularly important in cancer when long-term hazards are quite possible because of the biological mechanisms of the treatments used. Although observational studies may help to investigate these, systematic reviews of the relevant randomized trials from far enough in the past will have the substantial benefit of the removal of systematic bias. One such investigation has been performed (Cuzick et al, 1994) for a subset of the trials of radiotherapy after surgery for breast cancer, in which detailed information on causes of death was sought. This found an excess of cardiovascular deaths in the period more than 10 years after primary treatment for women allocated to receive radiotherapy. These trials used old radiotherapy techniques so it is unclear how directly applicable the findings are to modem techniques. But, it was still important to find that radiotherapy can produce such hazards and the individual trials were too small to investigate this reliably.
DISCUSSION
The two ways of collecting large-scale randomized evidence: large prospective randomized trials and systematic reviews of past trials are complementary. Systematic reviews that contain IPD metaanalyses might generate hypotheses about particular interventions or subgroups for testing in future trials and they can also foster international collaboration that might help to facilitate the conduct of randomized trials that are sufficiently large to investigate reliably any promising new treatments. For example, two large trials were started (Le Pechoux et al, 1995; Stephens et al, 1996) after the IPD meta-analysis of chemotherapy in non-small-cell lung cancer (Non-Small Cell Lung Cancer Collaborative Group, 1995) .
CONCLUSION
This report highlights the need for reviewers to consider whether systematic reviews in cancer should involve updated and centrally collected data on each and every randomized patient. An IPD meta-analysis may require more time and resources than some other techniques for systematic review, but it should lead to a more reliable assessment of the treatments under investigation. 
